Moleculin Biotech receives Hong Kong patent for Annamycin reconstitution method
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
May 8, 2026 8:45 AM EDTSolid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release
HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), today announced a significant advancement in its intellectual property portfolio with the issuance of a Hong Kong patent covering its proprietary method of reconstituting liposomal Annamycin.
The newly granted patent (No. 40073244), titled Method of Reconstituting Liposomal Annamycin, extends protection through June 25, 2040, further reinforcing Moleculins long-term global exclusivity strategy. The invention is jointly owned with The University of... More
